Esanex Inc.
12
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
33.3%
4 terminated/withdrawn out of 12 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
25%
2 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL
Role: lead
Study of SNX-5422 in TP53 Null Cancers
Role: lead
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
Role: lead
Safety and Activity of SNX-5422 Plus Ibrutinib in CLL
Role: lead
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors
Role: lead
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
Role: lead
Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers
Role: lead
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma
Role: lead
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
Role: lead
Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies
Role: lead
Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas
Role: lead
Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
Role: lead
All 12 trials loaded